Toboroz
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
EMG-Directed Virtual-Reality Training for Motor Stroke Rehabilitation
NCT07705256· Imperial College London· Forrás
Contact: Paul Bentley, PhD in Cognitive Neuroscience
Toboroz
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610· 3. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· 3. fázis· NovoCure GmbH· Forrás
Toboroz
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301· 3. fázis· NovoCure GmbH· Forrás
Toboroz
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345· 3. fázis· Telix Pharmaceuticals (Innovations) Pty Limited· Forrás
Contact: Amalia Saucan
Toboroz
Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)
NCT06280781· Imperial College London· Forrás
Contact: Archana Gopalakrishnan
Fut, nem toboroz
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
NCT05976685· Insel Gruppe AG, University Hospital Bern· Forrás
Contact: Lucio D'Anna, MD, MSc, PhD
Toboroz
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Contact: Farah Rehman
Fut, nem toboroz
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
NCT06511648· 2. fázis· Spanish Oncology Genito-Urinary Group· Forrás
Contact: Naveed Sarwar, MD, PhD
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891· EMD Serono Research & Development Institute, Inc.· Forrás
Contact: Joanne Evans (principal investigator)
Fut, nem toboroz
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888· 2. fázis· Biogen· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment
NCT04999423· Microvention-Terumo, Inc.· Forrás
Toboroz
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· 2/3. fázis· DiaMedica Therapeutics Inc· Forrás
Contact: Vaishali Dave
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· 3. fázis· Eisai Inc.· Forrás
Toboroz
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532· 3. fázis· University College, London· Forrás
Contact: Naveed Sarwar (principal investigator)
Fut, nem toboroz
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT03436485· 1/2. fázis· Orion Corporation, Orion Pharma· Forrás
Fut, nem toboroz
H1 Hip Resurfacing Arthroplasty
NCT03326804· Embody Orthopaedic Limited· Forrás
Fut, nem toboroz
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Vercise™ DBS Dystonia Prospective Study
NCT02686125· Boston Scientific Corporation· Forrás
Contact: Boston Scientific Clinical Research
Fut, nem toboroz
Correction of Angular Deformities in Knee Arthrosis
NCT02581605· Imperial College London· Forrás
Toboroz
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134· Boston Scientific Corporation· Forrás
Contact: Boston Scientific Clinical Research Manager
Fut, nem toboroz
Prostate Advances in Comparative Evidence
NCT01584258· 3. fázis· Royal Marsden NHS Foundation Trust· Forrás
Fut, nem toboroz
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
NCT00268476· 2/3. fázis· Medical Research Council· Forrás